T-cell treatment for EBV-positive lymphomas
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase study tests a lab-made immune cell treatment (cytotoxic T-lymphocytes) for certain lymphomas and related diseases that test positive for the Epstein-Barr virus (EBV). It may help your immune system attack EBV-infected cancer cells, especially after the cancer has come back or when transplant isn’t suitable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an EBV-positive lymphoma or related EBV condition (tumor test may still be pending at first)
- Your body weight is at least 12 kg (about 26 lb)
- You must have had recent treatment gaps: stop other research treatments 4 weeks before starting this study
- Your test results must be safe enough for treatment (blood counts, liver and kidney labs within allowed ranges)
- You need adequate oxygen levels without extra oxygen (oxygen on room air over 90%)
- If you can become pregnant, you must use effective birth control during the study and for 6 months after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new T-cell therapy (EB103) for people with B-cell non-Hodgkin's lymphoma that has come back or stopped responding to treatment. It aims to see if the therapy is safe and effective.
This trial tests nivolumab (an immune therapy) for people with EBV-positive lymphoma or EBV-driven immune/lymph conditions. It may help shrink tumors or control the disease when standard treatments have not worked or are not suitable.
This Phase 1 study tests an immune-cell therapy made to recognize EBV (a common virus) in people whose lymphoma contains EBV. It may help control EBV-driven cancers, especially when standard treatment isn’t working or can’t be used.
This trial tests an immune therapy made from EBV-targeted T-cells to treat EBV infections that do not improve with standard anti-viral medicines. It may help by strengthening the body’s ability to fight EBV after certain transplants or immune problems.
This trial tests a new cell therapy (TCR-T cells) for people with EBV-positive lymphoma that has not responded to standard treatments or has come back. The therapy uses your own immune cells that have been specially trained to find and attack cancer cells carrying the EBV virus.
This trial tests whether special immune cells (called EBV-TCR-T cells) can help clear the Epstein-Barr virus in people who still have high virus levels after a stem cell transplant. It's an experimental therapy for those whose virus hasn't responded to standard care.
Hear when a new Lymphoproliferative Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.